Controversy over HRT’s effect on CV risk unravelled
26 Nov 2019
byDr Margaret Shi
Hormone replacement therapy (HRT) with conjugated equinestrogens (CEE) plus medroxyprogeserone acetate (MPA) or CEE alone does not increase the risk of cardiovascular (CV) mortality among postmenopausal women, according to an expert who reviewed 18-year follow-up data of the Women’s Health Initiative (WHI) randomized trials at the Endocrinology, Diabetes Metabolism Hong Kong (EDMHK) 2nd Annual Meeting.